Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2006

View Archived Issues

SurModics and X-Cell Medical collaborate on drug-eluting stent system

Lentigen and U. of Pennsylvania collaborate on lentiviral vector development

Interleukin Genetics studies link between IL-1 gene variations and osteoporosis

Cardiome Pharma reviews quarter

Preclinical and clinical efficacy of the novel antiinflammatory AN-0128 reported

Schering-Plough begins phase I with compound from Pharmacopeia collaboration

Positive preclinical findings for Phenylase

Clevidipine progressing though phase III trials

Codevelopment and comarketing agreements signed for ibandronic acid in Japan

New Indian trial to study bavituximab in combination with chemotherapy

CepTor files IND complete response to move Myodur into clinic

Can-Fite to develop CF-101 for psoriasis

Hemopure MAA accepted for review in U.K.

Panzem studied in phase II for hormone-refractory prostate cancer

Oxigene updates CA4P ophthalmology strategy and trial status

Bristol-Myers Squibb and Medivir collaborate on MIV-170 for HIV

STA-4783 doubles median progression-free survival in metastatic melanoma

Bevasiranib shows biological effect in wet AMD

NBI-56418 reduces pain scores in endometriosis patients

Abraxane approved for metastatic breast cancer in Canada

Recent Allergan and ACADIA patents report novel analgesic agents

Recent patents report novel therapeutic agents for lipoprotein disorders and obesity

Novel therapeutic agents for immune disorders, transplant rejection, etc.

Positive preclinical results for Abbott's novel DPP-IV inhibitor

Preliminary data on Schering-Plough's second-generation FPT inhibitor reported

Arena presents novel GPR119 agonist for the treatment of non-insulin dependent diabetes

Novel class of PDE4 inhibitors with improved safety profile reported

Analogues of acronycine show improved antitumor activity in vitro and in vivo

Chemoprotective effects of a seafood extract

PAC-1: potential tailored therapy for individual cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.